AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know
AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for March 5th
PFLT, COMM, BGC, NLY and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on March 5, 2025.
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU)
The heavy selling pressure might have exhausted for AC Immune (ACIU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
New Strong Buy Stocks for January 31st
ENS, SOPA, MC, SFIX and ACIU have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
AC Immune SA ACIU revealed data from a Phase 2 clinical trial of its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson's disease.
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
AC Immune (ACIU) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of $0.42. This compares to loss of $0.22 per share a year ago.
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024. The global Alzheimer's therapeutics market size is expected to surpass $8.18 billion by 2032.
